Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple Therapy for Type 1 Diabetes with Insulin, Semaglutide and Dapagliflozin
2018-004120-11Phase 3Unknown
- Sponsor
- NHS Greater Glasgow and Clyde
- Start
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of semaglutide, dapagliflozin and human insulin in diabetes mellitus type 1 (T1D) (3 arms), sponsored by NHS Greater Glasgow and Clyde. Primary endpoint: Change in HbA1c. Status: unknown.
02
Drugs
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2018-004120-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004120-11.